Humulin N (Nph) Cartridge (Insulin Human (Rdna))

Humulin N (Nph) Cartridge is indicated for the management of diabetes mellitus where basal insulin coverage is required.

• Provides intermediate‑acting insulin for Type 1 diabetes mellitus in adults and children who need basal control.
• Used as basal insulin in Type 2 diabetes mellitus, either alone or together with oral antidiabetic agents.
• Serves as adjunct therapy when rapid‑acting insulin is administered for mealtime glucose control.
• Offers a stable and predictable insulin profile for patients requiring consistent basal coverage, such as during periods of stable diet and activity.

• Humulin N contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation of the insulin receptor substrate, initiating the PI3‑kinase/Akt pathway, which promotes translocation of GLUT‑4 transporters to the cell membrane, enhancing glucose uptake. In the liver, insulin suppresses gluconeogenesis and stimulates glycogen synthesis, thereby lowering circulating glucose concentrations and improves overall metabolic homeostasis.

Like all insulin preparations, Humulin N may be associated with adverse reactions that vary in frequency and severity.

Common

• Hypoglycemia, especially if meals are missed or dosing is excessive.
• Local injection‑site reactions such as redness, swelling, or itching.
• Lipodystrophy or lipohypertrophy at repeated injection sites.
• Mild weight gain due to improved glucose utilization.
• Transient edema or fluid retention.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Anaphylactic or severe allergic reactions, including urticaria and angioedema.
• Hypokalemia resulting from rapid intracellular shift of potassium.
• Insulin antibody syndrome causing unpredictable glucose control.
• Life‑threatening anaphylaxis requiring emergency medical treatment.

Before initiating Humulin N therapy, several safety considerations should be reviewed.

• Regularly monitor blood glucose to adjust dosage and avoid hypoglycemia.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Assess pregnancy, lactation, and pediatric status; insulin may be required but dosing must be individualized.
• Avoid administering during active hypoglycemia; treat low blood sugar before the next dose.
• Store cartridges according to manufacturer instructions and protect from extreme temperatures.
• Educate patients on proper injection technique to minimize lipodystrophy.
• Review concomitant medications that may potentiate insulin effects.

Humulin N can interact with several drug classes, influencing its glucose‑lowering action.

Avoid

• Concurrent use of other insulin products without proper dose adjustment, which can cause severe hypoglycemia.
• High‑dose sulfonylureas combined with Humulin N without monitoring, increasing hypoglycemia risk.

Use with caution

• Beta‑blockers may mask hypoglycemia symptoms.
• Thiazide diuretics can raise blood glucose levels, requiring dose changes.
• Corticosteroids may increase insulin resistance, necessitating higher doses.
• ACE inhibitors and ARBs may potentiate insulin’s glucose‑lowering effect.
• Oral antidiabetic agents such as metformin or DPP‑4 inhibitors should be coordinated to avoid excessive glucose reduction.